COVA-322

N/A

Report date: 2022/11/25 17:31:10

Base Information

Drug NameCOVA-322

Drug Alias NameBispecific anti-TNF/IL-17A FynomAbCOVA-322

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin 17A inhibitorsTumor necrosis factor α inhibitors

TargetsInterleukin 17ATumor necrosis factor α

Therapy Area/IndicationsPlaque psoriasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCovagen Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCovagen Ag

Active IndicationsN/A

Inactive IndicationsPlaque psoriasis

Other Information

ATC CodeN/A